Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global Age Related Macular Degeneration (AMD) Market, by Drug Type
1.4.2 Global Age Related Macular Degeneration (AMD) Market, by Disease Type
1.4.3 Global Age Related Macular Degeneration (AMD) Market, by Distribution Channel
1.4.4 Global Age Related Macular Degeneration (AMD) Market, by Geography
1.5 Methodology for the research
Chapter 2. Market at a Glance
2.1 Key Highlights
Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints
3.3 Porter Five Forces Analysis
Chapter 4. Strategies deployed in Age Related Macular Degeneration (AMD) Market
Chapter 5. Global Age Related Macular Degeneration (AMD) Market by Drug Type
5.1 Global Aflibercept Market by Region
5.2 Global Ranibizumab Market by Region
5.3 Global Others Market by Region
Chapter 6. Global Age Related Macular Degeneration (AMD) Market by Disease Type
6.1 Global Wet Market by Region
6.2 Global Dry Market by Region
Chapter 7. Global Age Related Macular Degeneration (AMD) Market by Distribution Channel
7.1 Global Hospital Pharmacy Market by Region
7.2 Global Retail Pharmacy Market by Region
7.3 Global Online Pharmacy Market by Region
Chapter 8. Global Age Related Macular Degeneration (AMD) Market by Region
8.1 North America Age Related Macular Degeneration (AMD) Market
8.1.1 North America Age Related Macular Degeneration (AMD) Market by Drug Type
8.1.1.1 North America Aflibercept Market by Country
8.1.1.2 North America Ranibizumab Market by Country
8.1.1.3 North America Others Market by Country
8.1.2 North America Age Related Macular Degeneration (AMD) Market by Disease Type
8.1.2.1 North America Wet Market by Country
8.1.2.2 North America Dry Market by Country
8.1.3 North America Age Related Macular Degeneration (AMD) Market by Distribution Channel
8.1.3.1 North America Hospital Pharmacy Market by Country
8.1.3.2 North America Retail Pharmacy Market by Country
8.1.3.3 North America Online Pharmacy Market by Country
8.1.4 North America Age Related Macular Degeneration (AMD) Market by Country
8.1.4.1 US Age Related Macular Degeneration (AMD) Market
8.1.4.1.1 US Age Related Macular Degeneration (AMD) Market by Drug Type
8.1.4.1.2 US Age Related Macular Degeneration (AMD) Market by Disease Type
8.1.4.1.3 US Age Related Macular Degeneration (AMD) Market by Distribution Channel
8.1.4.2 Canada Age Related Macular Degeneration (AMD) Market
8.1.4.2.1 Canada Age Related Macular Degeneration (AMD) Market by Drug Type
8.1.4.2.2 Canada Age Related Macular Degeneration (AMD) Market by Disease Type
8.1.4.2.3 Canada Age Related Macular Degeneration (AMD) Market by Distribution Channel
8.1.4.3 Mexico Age Related Macular Degeneration (AMD) Market
8.1.4.3.1 Mexico Age Related Macular Degeneration (AMD) Market by Drug Type
8.1.4.3.2 Mexico Age Related Macular Degeneration (AMD) Market by Disease Type
8.1.4.3.3 Mexico Age Related Macular Degeneration (AMD) Market by Distribution Channel
8.1.4.4 Rest of North America Age Related Macular Degeneration (AMD) Market
8.1.4.4.1 Rest of North America Age Related Macular Degeneration (AMD) Market by Drug Type
8.1.4.4.2 Rest of North America Age Related Macular Degeneration (AMD) Market by Disease Type
8.1.4.4.3 Rest of North America Age Related Macular Degeneration (AMD) Market by Distribution Channel
8.2 Europe Age Related Macular Degeneration (AMD) Market
8.2.1 Europe Age Related Macular Degeneration (AMD) Market by Drug Type
8.2.1.1 Europe Aflibercept Market by Country
8.2.1.2 Europe Ranibizumab Market by Country
8.2.1.3 Europe Others Market by Country
8.2.2 Europe Age Related Macular Degeneration (AMD) Market by Disease Type
8.2.2.1 Europe Wet Market by Country
8.2.2.2 Europe Dry Market by Country
8.2.3 Europe Age Related Macular Degeneration (AMD) Market by Distribution Channel
8.2.3.1 Europe Hospital Pharmacy Market by Country
8.2.3.2 Europe Retail Pharmacy Market by Country
8.2.3.3 Europe Online Pharmacy Market by Country
8.2.4 Europe Age Related Macular Degeneration (AMD) Market by Country
8.2.4.1 Germany Age Related Macular Degeneration (AMD) Market
8.2.4.1.1 Germany Age Related Macular Degeneration (AMD) Market by Drug Type
8.2.4.1.2 Germany Age Related Macular Degeneration (AMD) Market by Disease Type
8.2.4.1.3 Germany Age Related Macular Degeneration (AMD) Market by Distribution Channel
8.2.4.2 UK Age Related Macular Degeneration (AMD) Market
8.2.4.2.1 UK Age Related Macular Degeneration (AMD) Market by Drug Type
8.2.4.2.2 UK Age Related Macular Degeneration (AMD) Market by Disease Type
8.2.4.2.3 UK Age Related Macular Degeneration (AMD) Market by Distribution Channel
8.2.4.3 France Age Related Macular Degeneration (AMD) Market
8.2.4.3.1 France Age Related Macular Degeneration (AMD) Market by Drug Type
8.2.4.3.2 France Age Related Macular Degeneration (AMD) Market by Disease Type
8.2.4.3.3 France Age Related Macular Degeneration (AMD) Market by Distribution Channel
8.2.4.4 Russia Age Related Macular Degeneration (AMD) Market
8.2.4.4.1 Russia Age Related Macular Degeneration (AMD) Market by Drug Type
8.2.4.4.2 Russia Age Related Macular Degeneration (AMD) Market by Disease Type
8.2.4.4.3 Russia Age Related Macular Degeneration (AMD) Market by Distribution Channel
8.2.4.5 Spain Age Related Macular Degeneration (AMD) Market
8.2.4.5.1 Spain Age Related Macular Degeneration (AMD) Market by Drug Type
8.2.4.5.2 Spain Age Related Macular Degeneration (AMD) Market by Disease Type
8.2.4.5.3 Spain Age Related Macular Degeneration (AMD) Market by Distribution Channel
8.2.4.6 Italy Age Related Macular Degeneration (AMD) Market
8.2.4.6.1 Italy Age Related Macular Degeneration (AMD) Market by Drug Type
8.2.4.6.2 Italy Age Related Macular Degeneration (AMD) Market by Disease Type
8.2.4.6.3 Italy Age Related Macular Degeneration (AMD) Market by Distribution Channel
8.2.4.7 Rest of Europe Age Related Macular Degeneration (AMD) Market
8.2.4.7.1 Rest of Europe Age Related Macular Degeneration (AMD) Market by Drug Type
8.2.4.7.2 Rest of Europe Age Related Macular Degeneration (AMD) Market by Disease Type
8.2.4.7.3 Rest of Europe Age Related Macular Degeneration (AMD) Market by Distribution Channel
8.3 Asia Pacific Age Related Macular Degeneration (AMD) Market
8.3.1 Asia Pacific Age Related Macular Degeneration (AMD) Market by Drug Type
8.3.1.1 Asia Pacific Aflibercept Market by Country
8.3.1.2 Asia Pacific Ranibizumab Market by Country
8.3.1.3 Asia Pacific Others Market by Country
8.3.2 Asia Pacific Age Related Macular Degeneration (AMD) Market by Disease Type
8.3.2.1 Asia Pacific Wet Market by Country
8.3.2.2 Asia Pacific Dry Market by Country
8.3.3 Asia Pacific Age Related Macular Degeneration (AMD) Market by Distribution Channel
8.3.3.1 Asia Pacific Hospital Pharmacy Market by Country
8.3.3.2 Asia Pacific Retail Pharmacy Market by Country
8.3.3.3 Asia Pacific Online Pharmacy Market by Country
8.3.4 Asia Pacific Age Related Macular Degeneration (AMD) Market by Country
8.3.4.1 China Age Related Macular Degeneration (AMD) Market
8.3.4.1.1 China Age Related Macular Degeneration (AMD) Market by Drug Type
8.3.4.1.2 China Age Related Macular Degeneration (AMD) Market by Disease Type
8.3.4.1.3 China Age Related Macular Degeneration (AMD) Market by Distribution Channel
8.3.4.2 Japan Age Related Macular Degeneration (AMD) Market
8.3.4.2.1 Japan Age Related Macular Degeneration (AMD) Market by Drug Type
8.3.4.2.2 Japan Age Related Macular Degeneration (AMD) Market by Disease Type
8.3.4.2.3 Japan Age Related Macular Degeneration (AMD) Market by Distribution Channel
8.3.4.3 India Age Related Macular Degeneration (AMD) Market
8.3.4.3.1 India Age Related Macular Degeneration (AMD) Market by Drug Type
8.3.4.3.2 India Age Related Macular Degeneration (AMD) Market by Disease Type
8.3.4.3.3 India Age Related Macular Degeneration (AMD) Market by Distribution Channel
8.3.4.4 South Korea Age Related Macular Degeneration (AMD) Market
8.3.4.4.1 South Korea Age Related Macular Degeneration (AMD) Market by Drug Type
8.3.4.4.2 South Korea Age Related Macular Degeneration (AMD) Market by Disease Type
8.3.4.4.3 South Korea Age Related Macular Degeneration (AMD) Market by Distribution Channel
8.3.4.5 Singapore Age Related Macular Degeneration (AMD) Market
8.3.4.5.1 Singapore Age Related Macular Degeneration (AMD) Market by Drug Type
8.3.4.5.2 Singapore Age Related Macular Degeneration (AMD) Market by Disease Type
8.3.4.5.3 Singapore Age Related Macular Degeneration (AMD) Market by Distribution Channel
8.3.4.6 Malaysia Age Related Macular Degeneration (AMD) Market
8.3.4.6.1 Malaysia Age Related Macular Degeneration (AMD) Market by Drug Type
8.3.4.6.2 Malaysia Age Related Macular Degeneration (AMD) Market by Disease Type
8.3.4.6.3 Malaysia Age Related Macular Degeneration (AMD) Market by Distribution Channel
8.3.4.7 Rest of Asia Pacific Age Related Macular Degeneration (AMD) Market
8.3.4.7.1 Rest of Asia Pacific Age Related Macular Degeneration (AMD) Market by Drug Type
8.3.4.7.2 Rest of Asia Pacific Age Related Macular Degeneration (AMD) Market by Disease Type
8.3.4.7.3 Rest of Asia Pacific Age Related Macular Degeneration (AMD) Market by Distribution Channel
8.4 LAMEA Age Related Macular Degeneration (AMD) Market
8.4.1 LAMEA Age Related Macular Degeneration (AMD) Market by Drug Type
8.4.1.1 LAMEA Aflibercept Market by Country
8.4.1.2 LAMEA Ranibizumab Market by Country
8.4.1.3 LAMEA Others Market by Country
8.4.2 LAMEA Age Related Macular Degeneration (AMD) Market by Disease Type
8.4.2.1 LAMEA Wet Market by Country
8.4.2.2 LAMEA Dry Market by Country
8.4.3 LAMEA Age Related Macular Degeneration (AMD) Market by Distribution Channel
8.4.3.1 LAMEA Hospital Pharmacy Market by Country
8.4.3.2 LAMEA Retail Pharmacy Market by Country
8.4.3.3 LAMEA Online Pharmacy Market by Country
8.4.4 LAMEA Age Related Macular Degeneration (AMD) Market by Country
8.4.4.1 Brazil Age Related Macular Degeneration (AMD) Market
8.4.4.1.1 Brazil Age Related Macular Degeneration (AMD) Market by Drug Type
8.4.4.1.2 Brazil Age Related Macular Degeneration (AMD) Market by Disease Type
8.4.4.1.3 Brazil Age Related Macular Degeneration (AMD) Market by Distribution Channel
8.4.4.2 Argentina Age Related Macular Degeneration (AMD) Market
8.4.4.2.1 Argentina Age Related Macular Degeneration (AMD) Market by Drug Type
8.4.4.2.2 Argentina Age Related Macular Degeneration (AMD) Market by Disease Type
8.4.4.2.3 Argentina Age Related Macular Degeneration (AMD) Market by Distribution Channel
8.4.4.3 UAE Age Related Macular Degeneration (AMD) Market
8.4.4.3.1 UAE Age Related Macular Degeneration (AMD) Market by Drug Type
8.4.4.3.2 UAE Age Related Macular Degeneration (AMD) Market by Disease Type
8.4.4.3.3 UAE Age Related Macular Degeneration (AMD) Market by Distribution Channel
8.4.4.4 Saudi Arabia Age Related Macular Degeneration (AMD) Market
8.4.4.4.1 Saudi Arabia Age Related Macular Degeneration (AMD) Market by Drug Type
8.4.4.4.2 Saudi Arabia Age Related Macular Degeneration (AMD) Market by Disease Type
8.4.4.4.3 Saudi Arabia Age Related Macular Degeneration (AMD) Market by Distribution Channel
8.4.4.5 South Africa Age Related Macular Degeneration (AMD) Market
8.4.4.5.1 South Africa Age Related Macular Degeneration (AMD) Market by Drug Type
8.4.4.5.2 South Africa Age Related Macular Degeneration (AMD) Market by Disease Type
8.4.4.5.3 South Africa Age Related Macular Degeneration (AMD) Market by Distribution Channel
8.4.4.6 Nigeria Age Related Macular Degeneration (AMD) Market
8.4.4.6.1 Nigeria Age Related Macular Degeneration (AMD) Market by Drug Type
8.4.4.6.2 Nigeria Age Related Macular Degeneration (AMD) Market by Disease Type
8.4.4.6.3 Nigeria Age Related Macular Degeneration (AMD) Market by Distribution Channel
8.4.4.7 Rest of LAMEA Age Related Macular Degeneration (AMD) Market
8.4.4.7.1 Rest of LAMEA Age Related Macular Degeneration (AMD) Market by Drug Type
8.4.4.7.2 Rest of LAMEA Age Related Macular Degeneration (AMD) Market by Disease Type
8.4.4.7.3 Rest of LAMEA Age Related Macular Degeneration (AMD) Market by Distribution Channel
Chapter 9. Company Profiles
9.1 Biogen, Inc.
9.1.1 Company Overview
9.1.2 Financial Analysis
9.1.3 Regional Analysis
9.1.4 Research & Development Expense
9.1.5 Recent strategies and developments:
9.1.5.1 Partnerships, Collaborations, and Agreements:
9.1.6 SWOT Analysis
9.2 Bayer AG
9.2.1 Company Overview
9.2.2 Financial Analysis
9.2.3 Segmental and Regional Analysis
9.2.4 Research & Development Expense
9.2.5 SWOT Analysis
9.3 Apellis Pharmaceuticals, Inc.
9.3.1 Company Overview
9.3.2 Financial Analysis
9.3.3 Segmental Analysis
9.3.4 Research & Development Expenses
9.3.5 Recent strategies and developments:
9.3.5.1 Approvals & Trails:
9.3.6 SWOT Analysis
9.4 Regeneron Pharmaceuticals, Inc.
9.4.1 Company Overview
9.4.2 Financial Analysis
9.4.3 Research & Development Expense
9.4.4 SWOT Analysis
9.5 F. Hoffmann-La Roche Ltd.
9.5.1 Company Overview
9.5.2 Financial Analysis
9.5.3 Segmental and Regional Analysis
9.5.4 Research & Development Expense
9.5.5 SWOT Analysis
9.6 Ionis Pharmaceuticals, Inc.
9.6.1 Company Overview
9.6.2 Financial Analysis
9.6.3 Research & Development Expenses
9.6.4 SWOT Analysis
9.7 Novartis AG
9.7.1 Company Overview
9.7.2 Financial Analysis
9.7.3 Segmental and Regional Analysis
9.7.4 Research & Development Expense
9.7.5 Recent strategies and developments:
9.7.5.1 Approvals & Trails:
9.7.5.2 Acquisition and Mergers:
9.7.6 SWOT Analysis
9.8 Sanofi S.A.
9.8.1 Company Overview
9.8.2 Financial Analysis
9.8.3 Segmental and Regional Analysis
9.8.4 Research & Development Expense
9.8.5 SWOT Analysis
9.9 Coherus Biosciences, Inc.
9.9.1 Company Overview
9.9.2 Financial Analysis
9.9.3 Research & Development Expenses
9.9.4 Recent strategies and developments:
9.9.4.1 Approvals & Trials:
9.9.5 SWOT Analysis
9.1 Bausch Health Companies, Inc.
9.10.1 Company Overview
9.10.2 Financial Analysis
9.10.3 Segmental and Regional Analysis
9.10.4 Research & Development Expense
9.10.5 Recent strategies and developments:
9.10.5.1 Product Launches and Product Expansions:
9.10.6 SWOT Analysis
Chapter 10. Winning Imperative for Age Related Macular Degeneration (AMD) Market
Unique Offerings 
